Publications database | www.emcdda.europa.eu

Displaying 1 - 15 of 15

cover EMCDDA trendspotter briefing March 2021 Impact of COVID-19 on drug use and drug services in Western Balkans

Ad hoc publication

EMCDDA trendspotter briefing: Impact of COVID-19 on drug use and drug services in Western Balkans

The Western Balkans (Albania, Bosnia and Herzegovina, Kosovo*, Montenegro, North Macedonia and Serbia) registered the main waves of COVID-19 infections later than most of the EU countries, but containment strategies were implemented at the same time and with equal force as in the rest of Europe....

Cover page of the trendspotter briefing

Ad hoc publication

Impact of COVID-19 on drug markets, drug use, drug-related harms and responses in south European Neighbourhood Policy countries

Since the beginning of 2020, the world has been experiencing an unprecedented public health emergency caused by the coronavirus disease (COVID-19) pandemic, which has led to progressive introduction of social distancing and other control measures by national governments. To investigate the effects...

Publication cover

Rapid communication

New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic — an update from the EU Early Warning System

In this update from the the EU Early Warning System aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early warning and risk-assessment activities. The report covers the period until October 2020 and this year focuses on...

screenshot of meeting's webpage

Conference proceedings

Meeting report – Expert meeting on drug-related infectious diseases (DRID) 2020

This meeting report provides an overview of the content of the DRID meeting that took place online on 22-23 October 2020, focusing on: the direct and indirect impact of COVID-19 on drug users and harm reduction services involved in HIV, hepatitis and STI prevention, care and treatment; an...

Publication thumbnail

Ad hoc publication

Reitox national focal points’ activities during the COVID-19 pandemic

This report highlights the responses taken by the EMCDDA's Reitox network of national focal points to the COVID-19 crisis and describes the challenges met by the organisations and the strategies produced to overcome these challenges.

Ad hoc publication

EMCDDA trendspotter briefing: Impact of COVID-19 on drug markets, drug use, drug-related harms and responses in east European Neighbourhood Policy countries

Since the beginning of 2020, the world has been experiencing an unprecedented public health emergency caused by the coronavirus disease (COVID-19) pandemic, which has led to the progressive introduction of social distancing and other control measures by national governments. To investigate the...

publication cover

European Drug Report

European Drug Report 2020: Key Issues

This report, available in 24 languages, presents a summary of some the main findings of the 'European Drug Report 2020: Trends and Developments the EMCDDA’s latest analysis of the drug situation in Europe. The issues selected here have been chosen for their policy relevance and general interest.

European Drug Report

European Drug Report 2020: Trends and Developments

This report provides a comprehensive analysis of patterns emerging across Europe in the areas of drug supply, illicit drug use and associated public health problems. National data sets are also provided across these themes and on key harm-reduction interventions. The report is available in English...

Publication cover

Ad hoc publication

EMCDDA Trendspotter briefing: impact of COVID-19 on patterns of drug use and drug-related harms in Europe

Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this pandemic for people who use drugs in Europe, the EMCDDA instigated a mixed-...

Joint publications

EU Drug Markets — Impact of COVID-19

What effect is COVID-19 having on the drug market in the EU? This joint publication from the EMCDDA and Europol analyses the impact of the pandemic on the market for the main drug types (cannabis, heroin, cocaine, amphetamines, NPS), including demand, production, trafficking and availability. It...

screenshot of page

Ad hoc publication

Resources on COVID-19 and drug markets

This page describes the EMCDDA's ongoing work on the impact of the COVID-19 pandemic on drug markets in the EU. As well as showcasing EMCDDA publications on the topic, it also provides the reader with useful relevant resources from partner organisations. This resource is online only and may be...

screenshot of page

Ad hoc publication

COVID-19 resource page for people who use drugs (PWUD) and drug service providers

On this page, the EMCDDA has compiled examples of advice being issued to people who use drugs and service providers by some national bodies and different associations, networks and NGOs. This resource is online only and may be accessed here >>

Ad hoc publication

EMCDDA trendspotter briefing - Impact of COVID-19 on drug services and help-seeking in Europe

Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this outbreak for drug services in Europe, the European Monitoring Centre for...

Ad hoc publication

EMCDDA special report: COVID-19 and drugs – Drug supply via darknet markets

This report is a rapid and preliminary analysis of the impact of COVID-19 on selected online markets. Three relatively large darknet markets were reviewed for the purposes of this study, selected because of their importance to the EU market and because they could be accessed to provide information...

publication thumbnail

Ad hoc publication

EMCDDA update on the implications of COVID-19 for people who use drugs and drug service providers

COVID-19 is a major global health threat. People who use drugs face the same risks as those of the general population and therefore need to be aware of the appropriate advice to reduce their risk of infection. They can be exposed to additional risks, however, that require developing assessment and...

.

Loading